Cardiogenomics Testing Panels Market Report 2026

Cardiogenomics Testing Panels Market Overview

• Cardiogenomics Testing Panels market size has reached to $1.55 billion in 2025 • Expected to grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: Rising Prevalence Of Inherited Cardiovascular Diseases Driving The Market Growth Due To Advances In Genetic Testing And Early Diagnosis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiogenomics Testing Panels Market?

Cardiogenomics testing panels are genetic tests that analyze multiple genes to identify inherited risks for cardiovascular diseases, such as cardiomyopathies, arrhythmias, and familial hypercholesterolemia. They help in early diagnosis, personalized treatment, and family risk assessment. The main product types of cardiogenomics testing panels are single-gene panels, multi-gene panels, and whole exome sequencing panels. Single-gene panels are genetic tests that analyze one specific gene to detect mutations or variants associated with a particular inherited condition or disease. The technologies used include next-generation sequencing, PCR-based testing, microarrays, and others. These panels cover applications including inherited cardiovascular diseases, arrhythmias, cardiomyopathies, congenital heart diseases, and others, serving end users including hospitals and clinics, diagnostic laboratories, academic and research institutes, and others.

What Is The Cardiogenomics Testing Panels Market Growth Forecast?

The cardiogenomics testing panels market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to advancements in next-generation sequencing (NGS), integration of ai and bioinformatics in diagnostics, government initiatives supporting precision medicine, growing adoption of multi-gene and whole exome panels, increasing demand for personalized cardiovascular care. Major trends in the forecast period include personalized genetic risk profiling, ai-driven diagnostic tools, tele-cardiology and remote monitoring, integration of multi-gene panels, advanced bioinformatics platforms.

Global Cardiogenomics Testing Panels Market Segmentation

1) By Product Type: Single-Gene Panels, Multi-Gene Panels, Whole Exome Sequencing Panels 2) By Technology: Next-Generation Sequencing, PCR-Based Testing, Microarray, Other Technologies 3) By Application: Inherited Cardiovascular Diseases, Arrhythmias, Cardiomyopathies, Congenital Heart Diseases, Other Appications 4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users Subsegments: 1) By Single-Gene Panels: Ion Channel Gene Panels, Structural Heart Disease Gene Panels, Arrhythmia Gene Panels 2) By Multi-Gene Panels: Cardiomyopathy Panels, Arrhythmia Panels, Congenital Heart Disease Panels 3) By Whole Exome Sequencing Panels: Targeted Cardiovascular Exome Panels, Comprehensive Exome Panels, Research-Oriented Exome Panels

What Are The Drivers Of The Cardiogenomics Testing Panels Market?

The increasing prevalence of inherited cardiovascular diseases is expected to propel the growth of the cardiogenomics testing panels market going forward. Inherited cardiovascular diseases (ICDs) refer to a group of heart and blood vessel disorders that are passed down genetically from parents to children. The rise in inherited cardiovascular diseases is largely due to advances in genetic testing and diagnostics, enabling more accurate detection of previously undiagnosed cases. Cardiogenomics testing panels help in inherited cardiovascular diseases by analyzing a patient’s genes to identify mutations that cause hereditary heart conditions, enabling early diagnosis, risk assessment, and personalized treatment strategies. For instance, in February 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, in 2023, Blackpool recorded 185 deaths from cardiovascular disease, compared to 178 deaths in 2022. Therefore, the increasing prevalence of inherited cardiovascular diseases is driving the growth of the cardiogenomics testing panels industry. The increasing healthcare expenditure is expected to propel the growth of the cardiogenomics testing panels market going forward. Healthcare expenditure refers to the total amount of resources, including money spent by governments, private organizations, and individuals, on the provision, maintenance, and improvement of health services and medical care. Increasing healthcare expenditure is due to the rising prevalence of chronic diseases that require long-term treatment, continuous monitoring, and specialized medical interventions. Healthcare expenditure supports cardiogenomics testing panels by funding advanced genetic analyses that enable early detection, and prevention of inherited cardiovascular diseases, ultimately improving patient outcomes and reducing long-term costs. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, increasing healthcare expenditure drives the growth of the cardiogenomics testing panels industry.

Key Players In The Global Cardiogenomics Testing Panels Market

Major companies operating in the cardiogenomics testing panels market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Actia Group, Invitae Corporation, Fulgent Genetics Inc., GeneDx Inc., Ambry Genetics Corporation, Helix OpCo Inc., Centogene Gmbh, Blueprint Genetics Inc., Strand Life Sciences Pvt. Ltd., Genes2Me Pvt. Ltd., BioAro Inc., GENinCode Plc, Igenomix S.L., Asper Biotech Ltd.

What Are Latest Mergers And Acquisitions In The Cardiogenomics Testing Panels Market?

In May 2025, GeneDx Inc., a US-based genetic testing company, acquired Fabric Genomics Inc. for an undisclosed amount. With this acquisition, GeneDx aims to strengthen its genomic interpretation capabilities by integrating Fabric Genomics’ AI-driven variant interpretation platform, improving scalability and diagnostic insights across its testing servicesFabric Genomics, Inc. is a US-based genomics and bioinformatics company specializing in cardiogenomics testing panels and clinical genetic variant interpretation.

Regional Outlook

North America was the largest region in the cardiogenomics testing panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiogenomics Testing Panels Market?

The cardiogenomics testing panels market consists of revenues earned by entities by providing services such as genetic risk assessment, early diagnosis, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics testing panels market also includes sales of comprehensive cardiomyopathy panels, cardiac arrhythmia panels, and direct-to-consumer genomic profiles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.